Nispomeben

N/A

Report date: 2025/05/23 14:39:11
NME

Base Information

Drug NameNispomeben
Drug Alias NameE-1NRD.E1NRD-135SNRD135S-E1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase Lyn modulators
TargetsTyrosine-protein kinase Lyn
Therapy Area/IndicationsDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovaremed
China Registration ClassN/A

Develop Information

Active CompaniesNeuroFront Therapeutics (Hong Kong) LtdIcahn School Of Medicine At Mount SinaiNew York University
Inactive CompaniesNovaremed Ltd
Active IndicationsDiabetic Neuropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A